Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 346

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 346
---
eraCare Life Sciences Company), a full-scale clinical
and genomics research company, and is a former Board member of the New York State Clinical Lab Association and BioServe. Dr. Krenitsky
received a B.S. in business management from the University of Scranton and an M.D. from Jefferson Medical College (now the Sidney Kimmel
Medical College) in Philadelphia.

<div align='center'>199

MANAGEMENT FOLLOWING MERGER</div>

Immediately following the Merger,
the Combined Company Board will be composed of five (5) members, two (2) of whom have been designated by DiamiR Primary Stockholder
Parties and three (3) of whom has been designated by Aptorum and agreed to by DiamiR.

Effective as of the Effective
Time, the Aptorum board of directors will appoint the following DiamiR designees: Kira Sheinerman, Ph.D., MBA. and Laura A. Philips, and
the following Aptorum designee: Ian Huen, Justin Wu, and Douglas Arner to the board of directors of the Combined Company. Ian Huen is
expected to be appointed as Chair of the board of directors of the Combined Company. Alidad Mireskandari, Ph.D., MBA will be appointed
as a non-voting observer to the Board of the Combined Company. The current staggered structure of the Aptorum Board will adjust to a single
class of directors for the Combined Company following the completion of the Merger.

The right to designate directors
by Aptorum and DiamiR’s primary stockholder parties is only in connection with the closing of the Merger. Following the Merger,
pursuant to the Combined Company’s Certificate of Incorporation and By-laws, the full Board will be able to fill vacancies to the
Board by either the resignation or removal of current directors or by increasing the size of the Board. Additionally, other than the Board
exercising its power set forth above, all replacements, new nominees and re-elections of current Board members will be recommended by
the Nominating Committee of the Board of Directors and approved by the current Board of Directors for submission to the Combined Company’s
stockholders to be voted upon at the Combined Company’s Annual or Special Meetings. Following the Merger, neither Aptorum nor the
DiamiR primary stockholder will have any rights to designate any directors, nominees or replacement directors.

The following table lists names,
ages and positions of the individuals who are expected